Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity
Bioorganic & Medicinal Chemistry · 2026
DOI: 10.1016/j.bmc.2025.118477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026. Verfasst von Mai S El-Shoukrofy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt. Electronic address: mai.elshoukrofy@alex…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Aromatase Inhibitors, Benzoxazoles. Die Arbeit nennt 69 Literaturangaben.
Abstract (Originalsprache)
Novel anti-breast cancer benzoxazoles were synthesized applying the scaffold hopping and molecular hybridization approaches. MTT assay showed that 6 and 9b were 4.5 and 2 times more potent than doxorubicin against MCF-7 cells, while 9a and 13b were 10 and 7.5 times more effective against MDA-MB-231 cells, respectively. The four compounds showed good safety profiles toward MCF-10A cells' growth. Enzyme inhibition assays identified 9b as a potent aromatase (ARO) inhibitor, exhibiting twice the potency of letrozole. 13d was more potent PI3Kα inhibitor than pictilisib, while 6, 9a, and 13b were multi-kinase inhibitors. Compound 9a was 2 and 2.5 times more potent than lapatinib against EGFRWT and EGFRL858R, besides being a selective PI3Kα/β inhibitor, surpassing pictilisib by 3 and 1.5 times, respectively. Compound 13b exhibited comparable EGFRL858R inhibition to lapatinib and outperformed pictilisib against PI3Kα, PI3Kβ, and PI3Kδ. Compound 6 showed greater ARO inhibition than letrozole, while being slightly less potent than pictilisib against PI3Kα and PI3Kβ. The four compounds downregulated p-ERK and/or p-AKT levels more effectively than letrozole or lapatinib. They elevated Beclin-1 levels and increased caspase-9 levels with 6, 9a and 9b inducing higher %total apoptosis than doxorubicin in annexin V/ propidium iodide assay. Moreover, 9a reduced cell migration and invasion percentages to 9.22 and 16.95 %, respectively, in MDA-MB-231-treated cells, thereby suppressed metastasis. Docking studies supported the in vitro enzymatic inhibition assays results. Thus, 9b and 13d are potent anti-breast cancer benzoxazoles with selective ARO and PI3kα inhibition activity, respectively, while 6, 9a, and 13b are multi-target inhibitors exhibiting other anticancer synergistic mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt. Electronic address: mai.elshoukrofy@alexu.edu.eg.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, 21521 Alexandria, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Damanhour University, 22511 Damanhour, Egypt.
Zitieren
APA
El-Shoukrofy, M. S., Amr, M. E., Okda, T. M., Omar, A. M. E., & AboulWafa, O. M. (2026). Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2025.118477
Vancouver
El-Shoukrofy MS, Amr ME, Okda TM, Omar AME, AboulWafa OM. Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity. Bioorganic & Medicinal Chemistry. 2026. doi:10.1016/j.bmc.2025.118477
BibTeX
@article{ElShoukrofy2026,
author = {El-Shoukrofy, Mai S and Amr, Mai E and Okda, Tarek M and Omar, A-Mohsen M E and AboulWafa, Omaima M},
title = {Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity},
journal = {Bioorganic & Medicinal Chemistry},
year = {2026},
doi = {10.1016/j.bmc.2025.118477}
}
EUVIMED